Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/218909
Title: Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry
Author: Cobo Ibáñez, Tatiana
Castellví, Ivan
Pros, Ana
Domínguez Álvaro, Marta
Nuño Nuño, Laura
Martínez Barrio, Julia
Jovaní, Vega
Romero Bueno, Fredeswinda
Ruiz Lucea, Esther
Tomero, Eva
Trallero Araguás, Ernesto
Narváez, Javier
Camins Fàbregas, Jordi
Ruiz Román, Alberto
Loarce Martos, Jesús
Holgado, Susana
Flores Rodríguez, V. Miguel
Sivera, Francisca
Merino Argumanez, Carolina
Juan Mas, Antonio
Altabás González, Irene
Martín López, María
Belzunegui Otano, Joaquín María
Carrasco Cubero, Carmen
Freire González, Mercedes
Rúa Figueroa, Iñigo
Lozano Rivas, Nuria
Suarez Cuba, Julio David
Martínez, Olga
Ortega Castro, Rafaela
Alcocer, Patricia
Gómez Gómez, Alejandro
Sánchez Pernaute, Olga
Tandaipan, José Luis
Carrión Barberà, Irene
Plasencia Rodríguez, Chamaida
Ibarguengoitia Barrena, Oihane
Vidal Montal, Paola
Ortiz Santamaria, Vera
Garrido Puñal, Noemi
Riveros, Anne
Delgado Frías, Esmeralda
López Gómez, Juan Miguel
Barbadillo, Carmen
Pego Reigosa, José María
Joven, Beatriz
Valero Jaimes, Jesús Alejandro
Naveda, Elena
Turrión Nieves, Ana Isabel
Seoane Mato, Daniel
Prado Galbarro, Francisco Javier
Puche Larrubia, María Ángeles
Keywords: Miopaties inflamatòries idiopàtiques
Autoanticossos
Danys
Idiopathic inflammatory myopathies
Autoantibodies
Damage
Issue Date: 8-Jan-2025
Publisher: Springer Science and Business Media LLC
Abstract: Objective To evaluate the main outcomes of disease activity and their association with other measures of activity, damage, and quality of life in patients with idiopathic inflammatory myopathy (IIM) according to time since diagnosis and positivity to antisynthetase autoantibodies (ASAs). Methods Cross-sectional multicenter study within the Spanish Myo-Spain registry. Cases were classified as incident (<= 12 months since diagnosis) and prevalent. The main outcomes of disease activity were the Myositis Disease Activity Assessment visual analogue scale (MYOACT), the Manual Muscle Test 8 (MMT-8), physician global activity (PhGA), and extramuscular activity. Other measures of activity, damage, and quality of life included patient global disease activity, MYOACT muscular, creatine phosphokinase, Health Assessment Questionnaire, physician and patient global damage, global damage of the Myositis Damage Index, and the 12-item Short-Form Health Survey (SF-12). We analyzed associations using a multivariate generalized linear model and a simple linear regression model. Results A total of 554 patients with different diagnostic subgroups of IIM were included (136 incident and 418 prevalent cases), with 215 ASA-positive patients (58 incident and 157 prevalent cases). All measures of disease activity were higher in the incident cases (p < 0.05), except for MYOACT muscular and creatine phosphokinase, for which no differences were recorded in ASA-positive patients. No differences were found between incident and prevalent cases for measures of damage. Values for the physical component of the SF-12 were higher in the prevalent cases (p < 0.05). The multivariate model was initially significant overall for the main activity outcomes. Positivity to ASAs was positively and negatively associated with the MYOACT index and MMT-8, respectively (p < 0.05), although no association was recorded with PhGA and extramuscular activity. Prevalent cases were negatively associated with the main outcomes of activity, except with MMT-8, for which the association was positive (p < 0.05). Conclusions The main activity outcomes validated in polymyositis and dermatomyositis could also be used in other subtypes of IIM, such as antisynthetase syndrome. Recent diagnosis is associated with greater disease activity, as assessed based on these activity outcomes. PhGA and extramuscular activity are not modified by ASA positivity, thus supporting their preferred use for assessing treatment response in IIM with ASAs.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s13075-024-03471-x
It is part of: Arthritis Research & Therapy, 2025, vol. 27, num. 1
URI: https://hdl.handle.net/2445/218909
Related resource: https://doi.org/10.1186/s13075-024-03471-x
ISSN: 1478-6354
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s13075-024-03471-x.pdf865.01 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons